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Background: Rates and risk factors of local, axillary and supraclavicular recurrences can guide patient selection and
target for postmastectomy radiotherapy (PMRT).
Patients and methods: Local, axillary and supraclavicular recurrences were evaluated in 8106 patients enrolled in 13
randomized trials. Patients received chemotherapy and/or endocrine therapy and mastectomy without radiotherapy.
Median follow-up was 15.2 years.
Results: Ten-year cumulative incidence for chest wall recurrence of >15% was seen in patients aged <40 years
(16.1%), with ≥4 positive nodes (16.5%) or 0–7 uninvolved nodes (15.1%); for supraclavicular failures >10%: ≥4
positive nodes (10.2%); for axillary failures of >5%: aged <40 years (5.1%), unknown primary tumor size (5.2%), 0–7
uninvolved nodes (5.2%). In patients with 1–3 positive nodes, 10-year cumulative incidence for chest wall recurrence of
>15% were age <40, peritumoral vessel invasion or 0–7 uninvolved nodes. Age, number of positive nodes and number
of uninvolved nodes were signiﬁcant parameters for each locoregional relapse site.
Conclusion: PMRT to the chest wall and supraclavicular fossa is supported in patients with ≥4 positive nodes. With
1–3 positive nodes, chest wall PMRT may be considered in patients aged <40 years, with 0–7 uninvolved nodes or
with vascular invasion. The ﬁndings do not support PMRT to the dissected axilla.
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introduction
Postmastectomy radiotherapy (PMRT) in patients with breast
cancer reduces the risk of locoregional recurrence (LRR) by a
proportionate 60%–70% [1], and improvement in locoregional
control can impact overall survival (OS). The Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) overview
showed that one breast cancer death would be avoided for
every four LRR prevented [1]. The reported absolute risk of
LRR after mastectomy without radiotherapy (RT) varies widely
[2] and thus conclusions regarding indications for PMRT are
not uniform. Furthermore, the 4 : 1 ratio of LRR to OS
reported by the EBCTCG may differ among patient subgroups.
Kyndi et al. [3, 4] reported a larger translation of LRR
reduction into survival beneﬁt in patients with more favorable
prognostic factors, e.g. in hormone receptor-positive patients
compared with hormone receptor-negative or HER-2-positive
patients.
In addition to the indications for PMRT, there is also
controversy about the optimal radiation target volume. A
recent survey on the radiotherapeutic management of invasive
breast cancer in North America and Europe found marked
differences in physician opinions. For example, internal
mammary chain irradiation was offered more often by
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European than North American radiation oncologists, whereas
those from North America were more likely to irradiate the
supraclavicular fossa and axilla [5].
In a previous report from the International Breast Cancer
Study Group (IBCSG) 1138 LRR were recorded among 5352
breast cancer patients treated with mastectomy without PMRT
and followed for a median of 14.5 years: an overall LRR rate of
21.3%. Among these, the most common site of LRR in breast
cancer patients without PMRT was the chest wall (53%),
followed by the supra/infraclavicular region (26%) and the
axilla (13%). Tumor relapse at the internal mammary region
was rarely reported (1%) [6]. The number of positive axillary
nodes and tumor grade were signiﬁcant risk factors for LRR. In
addition, peritumoral vessel invasion (PVI) for premenopausal
patients and tumor size for postmenopausal patients were also
signiﬁcant prognostic factors [6]. In a subsequent IBCSG
study, the number of examined uninvolved nodes was found to
be a signiﬁcant risk factor for LRR [7]. In this study, patients
with 1–3 positive nodes in the presence of PVI, young age or
few uninvolved nodes had an increased risk of LRR.
The aim of the present analysis is to study the rates and risk
factors of local, axillary and supraclavicular recurrences
separately, not only to guide patient selection for PMRT but also
to guide radiation target volume when radiotherapy is indicated.
patients and methods
design of the studies
IBCSG Trials I–IX and 11–14 (13 trials in total) accrued 12 409 patients
from 1978 to 1999. Results of the treatment comparisons, detailed
deﬁnitions for menopausal status, patient characteristics and eligibility have
been described elsewhere [8–17] and are summarized in Supplementary
Table S1 (available at Annals of Oncology online). With the exception of
trial V, where patients were entered before the pathological work-up was
completed, patients were included only if the tumors were pT1, pT2 or pT3
and the resection margins were free of tumor cells. Study guidelines
required axillary dissection and that at least ﬁve (trials I–IV) or eight (trials
V–IX and 11–14) lymph nodes should be removed in the axillary
specimen. All patients on trials I–V were to receive mastectomy without
RT. Patients on trials VI–IX and 11–14 received either mastectomy without
RT or breast-conserving surgery, mostly with RT. Patients treated with
breast-conserving surgery were excluded from the present analysis. The 13
randomized trials evaluated the timing and/or duration of chemotherapy,
endocrine therapy, chemoendocrine therapy or no adjuvant therapy.
Institutional review boards reviewed and approved the protocols and
informed consent was required according to the criteria established within
the individual countries.
For trials I–V, VIII–IX and 11–14, a central pathology review process
included the histological evaluation of primary tumor specimens for
invasion of lymphatic or blood vessels around the primary tumor was
undertaken [18]. No central pathology review was conducted for trials VI–
VII, and the information about vessel invasion was provided by the local
pathology work-up from the participating centers. PVI was deﬁned as the
presence of tumor cell emboli within a vessel space, which were identiﬁed
by associated ﬁbrin clot and/or an endothelial cell lining. The study
protocol required that at least two sections of primary tumor be taken at
right angles to one another to include the interface of the growing tumor
border and the adjacent breast tissue. Generally, ∼6 cm2 of breast tissue
immediately adjacent to the primary tumor, but within 1 cm of the tumor
border, was available for the assessment of PVI.
patient selection
As in our previous reports [6, 7], the population studied comprised
patients assigned to receive total mastectomy without RT but with
adequate systemic treatment, deﬁned as three or more courses of classical
cyclophosphamide, methotrexate, and 5-ﬂuouricil (CMF) for
premenopausal node-positive patients, three or more courses of CMF or
tamoxifen for 1–5 years for postmenopausal node-positive patients,
chemotherapy and/or endocrine therapy for pre- and postmenopausal
node-negative patients or endocrine therapy alone for patients with
hormone receptor-positive tumors. These criteria resulted in the exclusion
of 768 patients who were assigned lesser adjuvant therapy and 3441
patients who received breast-conserving surgery. An additional 82 patients
who had PMRT were also excluded. Twelve patients were excluded due to
missing information regarding number of uninvolved nodes. The total
number of patients excluded was 4303, and the remaining 8106 patients
were included in this analysis.
statistical analysis
The following variables were deﬁned for the analysis: nodal involvement
status (0, 1–3, ≥4 lymph nodes involved), tumor size (≤2 or >2 cm),
estrogen receptor (ER) status (<10 or ≥10 fmol/mg of cytosol protein, or,
in later years, based on immunohistochemical results), age (<40, 40–49,
50–59, ≥60 years), histological grade (1, 2, 3) and PVI (yes or no). To
account for missing values, we included an additional category (unknown).
The number of uninvolved lymph nodes was deﬁned as the number of
nodes examined less the number of positive nodes.
This analysis considered the following four types of recurrences: local,
axillary, supraclavicular and distant. Internal mammary recurrences were
rarely reported (<1%) and were not included in this analysis [6]. Only the
ﬁrst documented recurrence, possibly in combination with other sites, was
considered.
The time to recurrence was determined as the number of years from
randomization until the ﬁrst proven recurrence or the date of last follow-up
(or death). If no recurrence or death was documented, then time to
recurrence was censored at the date of last follow-up. Statistical methods
for competing risks were used in this analysis, including cumulative
incidence estimation [19, 20] and competing risks regression analysis [21].
Results from competing risk regression analyses were converted to hazard
ratios. Analysis for each recurrence type was carried out separately. For
each type of recurrence, all other failures, including death, were treated as
competing risks. When evaluating a particular recurrence type, only those
other types of recurrence not in combination with the type of interest were
considered competing risks. Cumulative incidence curves were compared
using the method of Gray [20]. Wald tests [22] were used to determine
statistical signiﬁcance of each risk factor in the regression models, ﬁrst for
each risk factor overall and then for each individual hazard ratio. A two-
sided P value <0.05 was considered statistically signiﬁcant. To account for
multiple comparisons in the regression models, we considered a hazard
ratio to be statistically signiﬁcant if its two-sided P value was <0.05 and the
corresponding overall Wald test had a P value <0.05.
The inﬂuence of number of uninvolved nodes on recurrence risk was
descriptively evaluated using a subpopulation treatment effect pattern plot
(STEPP) analysis [23] in which patients were divided into overlapping
subgroups based on the number of uninvolved nodes. Each subgroup was
designed to contain at least 200 patients and to overlap with the previous
subgroup by at most 100 patients. The 10-year cumulative incidence of
recurrence was determined within each subgroup, and the results were
plotted on a graph (versus the midpoint of the interval) to illustrate how
risk changes as the number of uninvolved nodes increases.
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For the group of patients with 1–3 positive nodes, risk proﬁles
considering age, PVI and number of uninvolved nodes were modeled,
giving estimates of 10-year cumulative incidence for local, axillary and
supraclavicular relapse separately.
results
Table 1 summarizes the patients and tumor characteristics of
the 8106 eligible patients. The median follow-up for all patients
was 15.2 years and the trial-speciﬁc median follow-up ranges
from 9.7 to 25.3 years. The 10-year cumulative incidence of
local, axillary and supraclavicular recurrence in different
patients groups is also shown in Table 1. In general, the
absolute level of LRR was highest for the chest wall: a 10-year
cumulative incidence for local failure of >15% was documented
in patients below age 40 (16.1%), in ≥4 positive lymph nodes
(16.5%) and in patients with 0–7 uninvolved lymph nodes
(15.1%). In regard to supraclavicular failure, only patients with
≥4 positive lymph nodes exceeded a 10% cumulative risk level
(10.2%). Axillary failure rates were relatively rare with a risk far
below 10%. A 10-year cumulative risk of ∼5% could be
demonstrated for patients below age 40 (5.1%), ≥4 positive
lymph nodes (4.9%), patients with unknown tumor size (5.2%)
and patients with 0–7 uninvolved nodes (5.2%). Details are
given in Table 1.
The cumulative incidence of distant failure exceeded the
incidence of all sites of LRR in both node-positive and node-
negative patients (Figure 1).
Multivariable competing risk regression analyses for local,
axillary and supraclavicular recurrences are shown in Table 2.
Age, number of positive lymph nodes and number of
uninvolved lymph nodes were highly signiﬁcant parameters for
all individual locoregional relapse sites. The risk for
supraclavicular recurrence was lower in patients with positive
ER status [hazard ratio = 0.71, 95% conﬁdence interval (CI)
0.58–0.87, Table 2] compared with negative ER status. Larger
tumor size and PVI were signiﬁcant predictors for local und
supraclavicular failure but only of borderline signiﬁcance for
axillary relapse. Tumor differentiation, especially grade 3, was a
highly signiﬁcant predictor for supraclavicular failure (Table 2).
A descriptive STEPP analysis shows a decreased risk of local,
axillary, supraclavicular as well as distant recurrences with
increasing number of uninvolved nodes examined
(Supplementary Figure S1, available at Annals of Oncology
online).
Looking speciﬁcally at patients with 1–3 positive nodes, risk
proﬁles considering age, PVI and number of uninvolved nodes
were modeled giving estimates of 10-year cumulative incidence
separately for chest wall, axillary and supraclavicular
recurrences (Supplementary Table S2, available at Annals of
Oncology online). All patients <40 years at diagnosis and
almost all groups of patients with PVI or 0–7 uninvolved
nodes had >10% 10-year cumulative incidence for chest wall
relapse (Supplementary Table S2, available at Annals of
Oncology online). For axillary recurrences, only patients <40
years combined with PVI and low numbers of uninvolved
nodes had 10-year axillary relapse rates above 5%. For
supraclavicular relapse, the combination of PVI and low
numbers of uninvolved nodes had relapse rates above 5%.
discussion
In our study of 8106 patients treated with mastectomy without
RT, the absolute LRR rates at the chest wall, axilla and
supraclavicular fossa varied. Generally, the risk factors for
locoregional failure at any site were also risk factors for the
individual anatomical subsites with the exception of ER status.
Positive ER status was found to be associated with an increased
risk of recurrence at the chest wall but not the supraclavicular
fossa. This may be a chance ﬁnding, as a study by Kyndi et al.
reported a greater survival beneﬁt of PMRT in patients with
ER-positive disease, in which a prevented isolated chest wall
recurrence might be more meaningful in diminishing the risk
for subsequent distant spread of the disease.
Table 1. Ten-year cumulative incidence of local recurrence, axillary
recurrence and supraclavicular recurrence










<40 949 (12) 16.1 (1.2) 5.1 (0.7) 6.3 (0.8)
40–49 2607 (32) 10.5 (0.6) 2.7 (0.3) 6.1 (0.5)
50–59 2452 (30) 9.6 (0.6) 2.4 (0.3) 6.3 (0.5)
≥60 2098 (26) 10.8 (0.7) 2.5 (0.3) 3.5 (0.4)
Nodes involved
None 2555 (32) 6.8 (0.5) 1.3 (0.2) 2.2 (0.3)
1–3 3260 (40) 10.3 (0.5) 2.6 (0.3) 4.8 (0.4)
4–10 1744 (22) 15.4 (0.9) 4.9 (0.5) 8.8 (0.7)
≥11 547 (7) 19.9 (1.7) 4.9 (0.9) 14.8 (1.5)
Tumor size, cm
≤2 3200 (39) 8.7 (0.5) 2.4 (0.3) 3.5 (0.3)
>2 4623 (57) 12.4 (0.5) 3.0 (0.3) 7.0 (0.4)
Unknown 283 (3) 12.9 (2.1) 5.2 (1.4) 3.8 (1.2)
Tumor grade
1 1126 (14) 8.2 (0.8) 1.3 (0.4) 2.0 (0.4)
2 3520 (43) 10.7 (0.5) 2.6 (0.3) 4.3 (0.3)
3 3036 (37) 12.3 (0.6) 3.5 (0.3) 8.4 (0.5)
Unknown 424 (5) 11.1 (1.6) 3.8 (0.9) 4.5 (1.0)
Estrogen receptor status
Negative 2383 (29) 10.6 (0.6) 3.1 (0.4) 7.7 (0.5)
Positive 4760 (59) 11.3 (0.5) 2.5 (0.2) 4.4 (0.3)
Unknown 963 (12) 10.0 (1.0) 3.6 (0.6) 5.5 (0.7)
Peritumoral vessel invasion
No 3823 (47) 8.6 (0.5) 2.0 (0.2) 3.8 (0.3)
Yes 2754 (34) 14.1 (0.7) 3.8 (0.4) 7.5 (0.5)
Unknown 1529 (19) 11.3 (0.8) 3.3 (0.5) 6.2 (0.6)
Nodes uninvolved
0–7 1925 (24) 15.1 (0.8) 5.2 (0.5) 9.3 (0.7)
8–11 1953 (24) 11.4 (0.7) 2.9 (0.4) 5.6 (0.5)
12–16 2126 (26) 9.8 (0.7) 2.2 (0.3) 4.3 (0.4)
≥17 2102 (26) 7.9 (0.6) 1.3 (0.2) 3.2 (0.4)
Nodes examined
≤10 1940 (24) 12.5 (0.8) 3.8 (0.4) 5.7 (0.5)
11–14 2076 (26) 9.4 (0.6) 3.5 (0.4) 6.0 (0.5)
15–19 2053 (25) 11.7 (0.7) 2.2 (0.3) 5.3 (0.5)
≥20 2037 (25) 10.3 (0.7) 2.0 (0.3) 5.1 (0.5)
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In the Danish and Canadian randomized trials, which
demonstrated a breast cancer-speciﬁc survival advantage of
PMRT, the radiation target volume included both the chest
wall and regional lymph nodes in the axilla, supraclavicular
fossa and internal mammary chain [24–26]. However, it is
unclear if comprehensive locoregional RT as prescribed in the
Danish and Canadian trials is essential for the survival
improvement or RT to a more limited target volume may
achieve comparable outcome. Controversial reports about the
LRR rates and the potential harmful effects of large-ﬁeld
comprehensive locoregional irradiation such as cardiovascular
morbidity, lymphedema, pneumonitis and brachial plexopathy
[1, 27, 28] leave this issue unresolved.
It is well accepted that patients with ≥4 positive nodes
should receive PMRT to the chest wall [29]. Several guidelines
also advise additional irradiation of the supraclavicular lymph
nodes in these patients [30] (http://www.nccn.org/
professionals/physician_gls/PDF/breast.pdf; http://www.
senologie.org/download/pdf/s3_leitlinie_en.pdf ). In our study,
patients with ≥4 positive nodes had the highest 10-year
cumulative incidence of local (16.1%) and supraclavicular
failure rates (10.2%). This ﬁnding is consistent with the study
by Strom et al. [31], who found a 15% risk for supraclavicular
failure at 10 years in patients with ≥4 positive nodes after
mastectomy. Furthermore, we observed the highest hazard
ratio (3.28, 95% CI 2.37–4.53) for supraclavicular failure in
patients with ≥4 positive nodes compared with node-negative
patients, which was highly statistically signiﬁcant. These
ﬁndings support the inclusion of supraclavicular nodes in
PMRT for patients with ≥4 positive lymph nodes.
In contrast, failures in the dissected axilla were uncommon
with the reported failure rates of ∼3% [6, 31]. In our study, the
10-year cumulative incidence of axillary recurrence ranged
from 1.3% (grade 1 tumor, pN0 or ≥17 uninvolved nodes) to
∼5% (≥4 positive nodes; unknown tumor size age below 40 or
0–7 uninvolved nodes). Therefore, our data supports the
recommendations in many radiotherapy guidelines not to
irradiate the dissected axilla. This recommendation is also
appropriate for patients with positive nodes and extracapsular
tumor spread (10-year axillary failure rates 3.2% and 4.9% in
patients with 1–3 and ≥4 positive nodes, respectively) [32].
The most controversial aspect of PMRT is its impact on
patients with 1–3 positive lymph nodes. The EBCTCG
overview showed that PMRT reduced LRR rates (5-year
absolute gain of 16.1%) and resulted in a statistically signiﬁcant
improvement of breast cancer mortality (15-year absolute gain
of 8.1%, P = 0.001) in these patients [33]. Despite this level I
evidence, the necessity for PMRT in patients with 1–3 positive
nodes remains contentious because the overview data are
mainly driven by the Danish trials, which had a number of
extensively discussed therapeutic weaknesses. Seventy percent
of the St Gallen expert panel did not routinely recommend
PMRT in these patients but 72% would support its application
in the presence of additional risk factors including young age
or PVI [29]. The retrospectively constructed risk proﬁles for
patient with 1–3 positive nodes in our study found a 10-year
risk level for chest wall recurrence of >10% in patients aged
<40 years; PVI was present; or there were fewer than eight
uninvolved nodes. This ﬁnding may indicate that at least chest
wall radiotherapy should be considered in these groups, which
is also supported by data from MacDonald et al. [34].
Furthermore, only patients with both PVI and fewer than eight
uninvolved nodes had a relapse risk level in the supraclavicular
fossa of >5% and only patients with a combination of all three
risk factors of age <40 years, PVI and fewer than eight
uninvolved nodes had a relapse rate in the axilla of >5%. These
observations may inform appropriate radiation target volume
but should be interpreted with caution due to the retrospective
character of our study. We used age, PVI and number of
uninvolved nodes in the risk proﬁles since they were the main
parameters for LRR in patients with 1–3 positive nodes and
dividing the proﬁles further would result in small numbers of
patients in each subgroup. Other studies yielded similar
supraclavicular recurrence rates ranging from 1% to 5% in
patients with 1–3 positive nodes [32, 35–39]. Yu et al. [40]
found lymphovascular invasion, extracapsular extension and
numbers and levels of involved axillary nodes as prognostic
factors for supraclavicular relapse and concluded that patients
with two or more of these risk factors might beneﬁt from
supraclavicular RT. The actively recruiting SUPREMO trial
(http://www.supremo-trial.com) evaluates the role of PMRT in
patients with 1–3 positive nodes. A recently reported phase III
Figure 1. Cumulative incidence of local, axillary, supraclavicular and distant recurrence according to nodal status at diagnosis for node-negative (A), 1–3
positive nodes (B) and ≥4 positive node (C) subpopulations.
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randomized trial by Whelan et al. [41] shows a signiﬁcant
disease-free survival advantage of breast plus regional nodal
RT compared with breast RT alone in patients treated with
breast-conserving therapy of whom 85% had 1–3 positive
nodes. However, whether this ﬁnding is equally applicable for
selected patient subgroups that had a mastectomy remains to
be conﬁrmed.
Our study found a reduced risk of any type of LRR with
increasing number of examined uninvolved nodes
(Supplementary Figure S1). This ﬁnding is in line with other
studies [42, 43]. Although the number of uninvolved nodes
Table 2. Full model multivariable Analysis of local recurrence (A), axillary
recurrence (B), and supraclavicular recurrence (C)




40–49 0.68 (0.56–0.83) 0.0001
50–59 0.63 (0.51–0.77) <0.0001
≥60 0.70 (0.57–0.86) 0.0009
Nodes involved
None 1.00 <0.0001
1–3 1.34 (1.11–1.60) 0.0017
4–10 1.85 (1.51–2.27) <0.0001
≥11 2.10 (1.60–2.74) <0.0001
Tumor size, cm
≤2 1.00 0.012
>2 1.22 (1.06–1.40) 0.0066
Unknown 1.43 (0.99–2.07) 0.059
Tumor grade
1 1.00 0.31
2 1.14 (0.92–1.42) 0.22
3 1.23 (0.99–1.54) 0.063
Unknown 1.13 (0.78–1.64) 0.53
Estrogen receptor status
Negative 1.00 0.084
Positive 1.18 (1.01–1.37) 0.039
Unknown 1.02 (0.81–1.29) 0.84
Peritumoral vessel invasion
No 1.00 <0.0001
Yes 1.40 (1.21–1.62) <0.0001
Unknown 1.08 (0.90–1.31) 0.42
Nodes uninvolved
0–7 1.00 0.014
8–11 0.96 (0.80–1.15) 0.63
12–16 0.90 (0.75–1.09) 0.30




40–49 0.59 (0.41–0.85) 0.0043
50–59 0.53 (0.36–0.77) 0.0010
≥60 0.57 (0.38–0.85) 0.0061
Nodes involved
None 1.00 0.0024
1–3 1.66 (1.09–2.52) 0.019
4–10 2.44 (1.52–3.92) 0.0002
≥11 1.90 (1.06–3.41) 0.031
Tumor size, cm
≤2 1.00 0.087
>2 0.98 (0.74–1.30) 0.88
Unknown 1.82 (1.03–3.22) 0.039
Tumor grade
1 1.00 0.053
2 1.58 (0.96–2.58) 0.070
3 1.94 (1.18–3.19) 0.0090





Risk factor Hazard ratio (95% CI) P valuea
Positive 0.98 (0.73–1.31) 0.87
Unknown 1.10 (0.73–1.64) 0.65
Peritumoral vessel invasion
No 1.00 0.055
Yes 1.41 (1.04–1.91) 0.027
Unknown 1.06 (0.73–1.55) 0.75
Nodes uninvolved
0–7 1.00 <0.0001
8–11 0.69 (0.49–0.97) 0.031
12–16 0.55 (0.38–0.80) 0.0018




40–49 1.12 (0.83–1.51) 0.47
50–59 1.24 (0.92–1.68) 0.16
≥60 0.71 (0.50–1.00) 0.049
Nodes involved
None 1.00 <0.0001
1–3 1.94 (1.42–2.64) <0.0001
4–10 3.02 (2.17–4.20) <0.0001
≥11 4.39 (2.95–6.55) <0.0001
Tumor size, cm
≤2 1.00 0.015
>2 1.35 (1.09–1.67) 0.0063
Unknown 0.87 (0.44–1.72) 0.68
Tumor grade
1 1.00 <0.0001
2 1.57 (1.05–2.35) 0.030
3 2.57 (1.72–3.84) <0.0001
Unknown 1.63 (0.84–3.16) 0.15
Estrogen receptor status
Negative 1.00 0.0035
Positive 0.71 (0.58–0.87) 0.0008
Unknown 0.83 (0.60–1.13) 0.24
Peritumoral vessel invasion
No 1.00 0.034
Yes 1.34 (1.07–1.67) 0.0095
Unknown 1.17 (0.88–1.54) 0.27
Nodes uninvolved
0–7 1.00 0.0014
8–11 0.86 (0.67–1.11) 0.25
12–16 0.77 (0.59–1.02) 0.064
≥17 0.54 (0.39–0.74) 0.0001
aOverall Wald test P values are shown in italics for each risk factor.
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may reﬂect individual anatomic variability, fewer uninvolved
nodes examined might be associated with inadequate surgery
or pathological understaging, which could lead to local or
systemic undertreatment. Other studies have shown that the
risk for LRR decreases with the total number of lymph nodes
examined [2] and the nodal ratio (proportion of lymph nodes
examined that contain tumor) is correlated to the risk for LRR
[44]. We have made a separate multivariable analysis in which
the number of uninvolved nodes is replaced by the total
number of examined nodes with very similar results (data not
shown). In the analyses for a former publication from our
group [7], we investigated a number of approaches to the
statistical modeling including the use of nodal ratios and found
that grouping patients into quartiles of positive nodes and
uninvolved nodes resulted in improved model ﬁt.
To conclude, in this analysis of 13 IBCSG randomized trials
involving over 8000 patients, the chest wall is the most
common site of locoregional failure sites after mastectomy.
Patients who were aged <40 years, had ≥4 positive nodes or
had 0–7 uninvolved nodes experienced a 10-year cumulative
incidence for local failure of ≥15%. PMRT to the chest wall
should be considered in these patients. Our study also supports
the application of supraclavicular RT in patients with ≥4
positive nodes. Irradiation of the dissected axilla is not
indicated. No clear recommendation on PMRT could be given
for patients with 1–3 positive nodes but PMRT to the chest
wall may be considered in the presence of the risk factors of
young age (<40 years), PVI or few uninvolved nodes (0–7).
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